Mark Baxter

We're not sure with the psilocybin-assisted program what the long-term results are, whether certain people might need like a yearly kind of treatment to hold the results.

We don't know that yet.

And the kinds of people that respond...

The kinds of people that don't, the kinds of people that respond, have a long-term treatment outcome, and the kinds of people that don't, we're sort of still needing to find that kind of information out.

But for people who have been stuck in depression for, you know, 10 years, to have 6 to 12 months of openness is a big deal.

It's life-changing, and it does give them the opportunity to try to make some key changes that can maybe, you know, embed something different.

Influence going forward.

Yeah.

So...

Yeah, the inclusion criteria, the exclusion criteria, and for some people, the contraindication is really important.

So just on accessibility, I'll say one of the things that is really difficult is that these are expensive treatments because there's so much therapy.

There's a lot of work that goes into it.

There's the medicines, the rooms, and everything like that.

You know, a three-dose, 12-session, four-to-five-month treatment period, we're talking about somewhere between $25,000 and $35,000.

So for most people, that is just inaccessible.

Out of reach, yeah.

So at the moment, the Department of Veterans Affairs has just signed off on facilitating a pathway for veterans for that.

Oh, great.

There's a lot of paperwork and it's difficult to get into, but you can do it.

And they're seeing this as an emerging treatment that they're interested in.